Evidence map›Paper›PMID 37948031›Full record

ReviewRheumatology and therapy2024

Epidemiology of Sjögren's: A Systematic Literature Review.

Eleanor Thurtle, Alice Grosjean, Monia Steenackers, Katharina Strege, Giovanna Barcelos, Pushpendra Goswami

Abstract readReview
In one paragraph

Review in Rheumatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Variants inInternational journal of molecular sciences · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Frontiers in immunology · 2026
    Article
  13. Article
  14. Sjogren's syndrome-Case series and literature review.Journal of oral and maxillofacial pathology : JOMFP · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Insights into Patient Heterogeneity in Sjögren's Disease.International journal of molecular sciences · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eleanor ThurtleCostello Medical, Cambridge, UK.
Alice GrosjeanSjögren's Patients Association for Western Switzerland, Vevey, Switzerland.
Monia SteenackersNovartis International AG, Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland.
Katharina StregeCostello Medical, Cambridge, UK.
Giovanna BarcelosNovartis International AG, Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland.
Pushpendra GoswamiNovartis International AG, Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland. pushpendra.goswami@novartis.com.ORCID http://orcid.org/0000-0002-3171-2495

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrimary Sjögren's is a multi-system autoimmune disease affecting patients' physical, mental, and emotional wellbeing. The epidemiology of Sjögren's is not well understood, and up-to-date epidemiological evidence is needed to improve knowledge and awareness of Sjögren's among patients and healthcare professionals, and to ascertain the global burden of disease. The objective of this research was to conduct a de novo systematic literature review (SLR) to identify and synthesise evidence on global epidemiology of primary Sjögren's.

methodsThis SLR was conducted in May 2021 by searching MEDLINE and Embase databases, relevant conference proceedings, websites of registries, and health technology assessment agencies and databases. Publications were systematically screened for English language articles reporting on the incidence, prevalence, age at symptom onset, and age at diagnosis for people with primary Sjögren's.

resultsOf 3510 records identified, 68 publications were included, representing 62 unique studies. Studies reported on age at symptom onset (16/62; 25.8%) and age at diagnosis (43/62; 69.4%) more frequently than incidence (7/62; 11.3%) and prevalence (9/62; 14.5%). Primary Sjögren's was found to have the highest incidence and prevalence in females and in older age groups (incidence: ≥65 years; prevalence: ≥75 years). Average age at onset and diagnosis of primary Sjögren's ranged between 34-57 years and 40-67 years, respectively.

conclusionsThis SLR identified a paucity of incidence and prevalence data for primary Sjögren's, highlighting a need for further epidemiological studies. The global Sjögren's community must work together to follow the defined classification criteria of primary Sjögren's and reporting guidelines for incidence and prevalence data to allow for meaningful epidemiological comparisons across studies, settings, and countries.

Indexed as

Autoimmune DiseaseDiagnosisEpidemiologyIncidenceOnsetPrevalenceSjögren’s Disease

Identifiers

PMID37948031
PMCPMC10796897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.